Cardiovascular Clinical Research

Cardiovascular Trial Startup: What 43 Days From Selection to First Screening Actually Shows

A 43-day cardiovascular startup result contains two distinct intervals. Here is what sponsors can learn from the handoffs between site selection, activation and first screening.

A research coordinator and physician review study readiness paperwork while another team member speaks with a participant in a bright clinic.

A site activation date is an important milestone in a cardiovascular study, but it is not the same as a participant screening date. A site may have completed contracts, approvals and training while still needing a suitable candidate, an investigator appointment and procedure-ready staff. Sponsors who combine those two intervals into one startup metric can miss where the actual work happened.

Wellness Clinical Research has published a phase 2b cardiovascular example: 43 calendar days from site selection to the first participant screened. The record separates 28 days from selection to activation and 15 additional days to first screening. It is one documented study, not a guaranteed timetable for future programs. The operational lesson is to manage regulatory readiness and patient readiness as connected but distinct paths.

Read the 43-day result as two intervals, not one promise

In the published case, the site was selected on July 15, 2026, activated on August 12 and screened its first participant on August 27. That is 28 calendar days from selection to activation, followed by 15 days from activation to first screening. The study team worked on budget, regulatory and institutional review board requirements while also preparing the candidate pipeline.

These dates describe site performance in a specific phase 2b cardiovascular protocol. They are not a universal startup benchmark, and the first screening does not establish randomization. The related case study reports that five people in the initial group subsequently randomized, without assigning a deadline for that outcome. Sponsors should preserve those distinctions when comparing startup performance.

The cardiovascular startup case study provides the source figures. Its value is the visibility of the two milestones, not an implication that every cardiovascular protocol can reach them on the same schedule.

Before activation: build a dependency map with accountable owners

Site startup is rarely a single sequential checklist. Budget and contract negotiations, essential documents, investigator information, ethics review, vendor access and protocol training often move at the same time. They are not independent, however. A completed contract does not replace IRB approval, and an approved consent form does not resolve missing lab kits or an untrained backup assessor.

At selection, the sponsor and site should establish one shared list of required deliverables. Record an owner, the party that can resolve a blocker, the evidence of completion and the earliest downstream activity affected. For example, an ECG vendor account may require delegation and training before qualification; a protocol amendment may affect both consent documents and training.

For a cardiovascular protocol, discuss which assessments occur locally and which need coordinated access. Available capabilities can include 12-lead ECG, blood-pressure measurement and sample processing, while other assessments or imaging may require approved external services. Verify the exact location, equipment, personnel, calibration and vendor dependencies for this protocol rather than relying on a generic capability list.

  • Contract and budget: confirm scope, patient travel and visit-related financial terms, with owners for open items.
  • Regulatory and ethics: map essential documents, IRB decisions, approved translations where required and site-specific conditions.
  • People and systems: verify investigator coverage, delegation, EDC and randomization access, vendor training and backup staff.
  • Procedures and supplies: confirm equipment, central lab setup, investigational product controls and visit-room readiness.

After activation: a scheduled screening still needs several conditions

An activation notice removes defined barriers, but it does not create an eligible participant. Cardiovascular protocols may combine diagnostic history, medication stability, recent events, laboratory thresholds, risk scores or biomarker requirements. Each screen can require record review, medical judgment and a realistic appointment slot. Database entries are not interchangeable with consenting, protocol-eligible people.

A useful feasibility and startup plan separates possible patient matches from people who can be contacted through approved processes, are interested in participating and have the time and willingness to complete screening. Teams should know whether outside records or specialist confirmations are necessary before a screening appointment. These checks must respect privacy and IRB-approved recruitment procedures.

A study visit may require a physician, coordinator, ECG assessment, blood collection and a quiet room in a defined sequence. A site that can offer one of those elements but not the whole sequence does not yet have a usable screening slot. Sponsors should ask for an executable first-visit plan that includes backup coverage and a clear approach to cancellations.

Use the activation-to-screening interval as a diagnostic measure

In the WCR cardiovascular example, the activation-to-first-screening interval was 15 days. The number becomes more informative when the sponsor asks what was ready on the day of activation. Were candidate conversations already underway through permissible channels? Did staff have working system access? Had visit windows, investigator appointments and required materials been checked?

A long interval does not by itself prove poor site performance. A rare eligibility profile, pending recruitment approval, an externally scheduled procedure or a study-specific seasonal condition may drive the timeline. Similarly, a very short interval does not prove broad enrollment capacity. Tracking the actual reasons is more useful than treating elapsed days as a standalone ranking.

Break early recruitment activity into interpretable steps: records reviewed, potential matches, candidates reached, candidates interested, screening appointments scheduled, screens completed and subsequent randomizations. Define each term once and avoid adding overlapping populations together. Report how much of the interval reflects site-controlled tasks versus sponsor, vendor or protocol dependencies.

Measure safety and quality readiness, not just speed

FDA regulations place responsibilities on sponsors to select qualified investigators and on investigators to conduct the study according to the signed commitments, protocol and applicable regulations while protecting participants. The FDA final ICH E6(R3) Good Clinical Practice guidance issued in September 2025 emphasizes risk-proportionate quality planning. An aggressive startup target cannot bypass required ethics approval, qualified oversight or informed consent.

For cardiovascular studies, safety oversight may include a defined process for clinically important ECG or laboratory findings, blood-pressure alerts, concomitant medications, adverse events and escalation to the investigator. The exact thresholds and reporting requirements come from the approved protocol and applicable requirements. Sponsors should verify how urgent decisions will be made during a busy screening day and who covers when the principal investigator is unavailable.

The most useful pre-activation rehearsal walks through a hypothetical screening visit. Confirm who greets and consents the participant, who verifies eligibility and conducts required assessments, how data enter the approved systems, and where specimens and safety reports go. A rehearsal can reveal practical gaps without exposing patient information or conducting study procedures before authorization.

A sponsor decision framework for the first 45 days

Rather than asking only for an estimated activation date, sponsors can request an operating view of the next several weeks. Each milestone should have one completion definition, a named dependency, an owner and a mitigation if it slips. Reconfirm assumptions whenever the protocol, vendor setup or recruitment approval changes.

At selection, review investigator fit and the proposed candidate sources. During startup, keep a shared blocker list with expected resolution and required evidence. Before activation, conduct readiness checks for consent documents, training, systems, study supplies and safety escalation. Immediately after activation, track screening slots and follow-up to candidate inquiries without claiming that an early screen equals enrollment.

A useful comparison between sites considers both elapsed time and the evidence behind it. One site may be fast on contracts but slow to secure participant appointments; another may have candidate conversations ready but needs additional vendor training. The assessment should identify the specific constraint and whether a feasible corrective action exists.

  • Day 0: confirm protocol fit, investigator responsibility, realistic patient sources and an agreed startup ownership map.
  • Before activation: verify all required approvals, contract and budget terms, documents, training, access, supplies and protocol-specific procedures.
  • At activation: document readiness and schedule a first-screening review with investigator and coordinator.
  • After activation: monitor candidate-to-screening conversion and distinguish screening from enrollment and randomization.
  • At each review: record blockers with owners, due dates, evidence of resolution and potential impact on participant safety or study quality.

How to apply this example without overgeneralizing

WCR operates coordinated clinical research services in Miami Lakes, Florida and Vega Baja, Puerto Rico. The published cardiovascular example shows a specific phase 2b startup sequence with parallel preparation and subsequent screening activity. It does not establish that every trial in either location will follow the same timeline, or that any future population will meet the same screening or randomization figures.

For a new study, the useful next step is a protocol-specific feasibility conversation: investigators, patient pathways, diagnostic and laboratory needs, expected visit burden, translations, vendor requirements and a realistic first-screening plan. Sponsors and CROs can use the existing Submit a Study process to share the protocol for evaluation.

Sources and further reading

Continue exploring

More from Wellness Clinical Research